UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2025 P 1411-3
Program Prior Authorization/Notification
Medication Daybue™ (trofinetide)
P&T Approval Date 5/2023, 5/2024, 5/2025
Effective Date 8/1/2025
1. Background:
Daybue is a synthetic analog of the amino-terminal tripeptide of insulin-like growth factor-1 (IGF-
1) indicated for the treatment of Rett syndrome (RTT) in adults and pediatric patients aged 2 years
and older.
2. Coverage Criteriaa:
A. Initial Authorization
1. Daybue will be approved based on BOTH of the following criteria:
a. Diagnosis of Rett Syndrome (RTT)
-AND-
b. Patient is 2 years of age or older
Authorization will be issued for 12 months.
B. Reauthorization
1. Daybue will be approved based on the following criterion:
a. Documentation of positive clinical response to Daybue therapy
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization
based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.
Use of automated approval and re-approval processes varies by program and/or therapeutic class.
© 2025 UnitedHealthcare Services Inc.
1
4. Reference:
1. Daybue [package insert]. San Diego, CA: Acadia Pharmaceuticals, Inc.; March 2023.
Program Prior Authorization/Notification - Daybue™ (trofinetide)
Change Control
Date Change
5/2023 New program.
5/2024 Annual review. Updated initial approval duration to 12 months.
5/2025 Annual review. No changes to clinical criteria.
© 2025 UnitedHealthcare Services Inc.
2